Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

Now Viewing

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

ALK Inhibitor Therapy Management

Main Discussion Topics

• Patient education strategies for lorlatinib therapy adherence
• Lipid-lowering interventions to support long-term lorlatinib treatment
• Monitoring tools for patients on ALK inhibitors
• Patient education methodologies specific to ALK inhibitor therapy

Discussion Questions Posed

• Grizzard inquired about proactive patient education and lipid-lowering interventions to help patients maintain lorlatinib therapy for long-term benefits

Castronovo asked about potentially useful tools for educating and monitoring patients on ALK inhibitors